Cargando…
Severity of COVID19 infection among patients with multiple sclerosis treated with interferon-β
BACKGROUND: Interferon-β, a disease-modifying therapy (DMT) for MS, may be associated with less severe COVID-19 in people with MS. RESULTS: Among 5,568 patients (83.4% confirmed COVID-19), interferon-treated patients had lower risk of severe COVID-19 compared to untreated, but not to glatiramer-acet...
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier B.V.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9310378/ https://www.ncbi.nlm.nih.gov/pubmed/35917745 http://dx.doi.org/10.1016/j.msard.2022.104072 |
| _version_ | 1784753372672294912 |
|---|---|
| author | Simpson-Yap, Steve Pirmani, Ashkan De Brouwer, Edward Peeters, Liesbet M. Geys, Lotte Parciak, Tina Helme, Anne Hillert, Jan Moreau, Yves Edan, Gilles Spelman, Tim Sharmin, Sifat McBurney, Robert Schmidt, Hollie Bergmann, Arnfin Braune, Stefan Stahmann, Alexander Middleton, Rodden Salter, Amber Bebo, Bruce van der Walt, Anneke Butzkueven, Helmut Ozakbas, Serkan Karabudak, Rana Boz, Cavit Alroughani, Raed Rojas, Juan I van der Mei, Ingrid Sciascia do Olival, Guilherme Magyari, Melinda Alonso, Ricardo Nicholas, Richard Chertcoff, Anibal Zabalza, Ana Arrambide, Georgina Nag, Nupur Descamps, Annabel Costers, Lars Dobson, Ruth Miller, Aleisha Rodrigues, Paulo Prčkovska, Vesna Comi, Giancarlo Kalincik, Tomas |
| author_facet | Simpson-Yap, Steve Pirmani, Ashkan De Brouwer, Edward Peeters, Liesbet M. Geys, Lotte Parciak, Tina Helme, Anne Hillert, Jan Moreau, Yves Edan, Gilles Spelman, Tim Sharmin, Sifat McBurney, Robert Schmidt, Hollie Bergmann, Arnfin Braune, Stefan Stahmann, Alexander Middleton, Rodden Salter, Amber Bebo, Bruce van der Walt, Anneke Butzkueven, Helmut Ozakbas, Serkan Karabudak, Rana Boz, Cavit Alroughani, Raed Rojas, Juan I van der Mei, Ingrid Sciascia do Olival, Guilherme Magyari, Melinda Alonso, Ricardo Nicholas, Richard Chertcoff, Anibal Zabalza, Ana Arrambide, Georgina Nag, Nupur Descamps, Annabel Costers, Lars Dobson, Ruth Miller, Aleisha Rodrigues, Paulo Prčkovska, Vesna Comi, Giancarlo Kalincik, Tomas |
| author_sort | Simpson-Yap, Steve |
| collection | PubMed |
| description | BACKGROUND: Interferon-β, a disease-modifying therapy (DMT) for MS, may be associated with less severe COVID-19 in people with MS. RESULTS: Among 5,568 patients (83.4% confirmed COVID-19), interferon-treated patients had lower risk of severe COVID-19 compared to untreated, but not to glatiramer-acetate, dimethyl-fumarate, or pooled other DMTs. CONCLUSIONS: In comparison to other DMTs, we did not find evidence of protective effects of interferon-β on the severity of COVID-19, though compared to the untreated, the course of COVID19 was milder among those on interferon-β. This study does not support the use of interferon-β as a treatment to reduce COVID-19 severity in MS. |
| format | Online Article Text |
| id | pubmed-9310378 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Elsevier B.V. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-93103782022-07-25 Severity of COVID19 infection among patients with multiple sclerosis treated with interferon-β Simpson-Yap, Steve Pirmani, Ashkan De Brouwer, Edward Peeters, Liesbet M. Geys, Lotte Parciak, Tina Helme, Anne Hillert, Jan Moreau, Yves Edan, Gilles Spelman, Tim Sharmin, Sifat McBurney, Robert Schmidt, Hollie Bergmann, Arnfin Braune, Stefan Stahmann, Alexander Middleton, Rodden Salter, Amber Bebo, Bruce van der Walt, Anneke Butzkueven, Helmut Ozakbas, Serkan Karabudak, Rana Boz, Cavit Alroughani, Raed Rojas, Juan I van der Mei, Ingrid Sciascia do Olival, Guilherme Magyari, Melinda Alonso, Ricardo Nicholas, Richard Chertcoff, Anibal Zabalza, Ana Arrambide, Georgina Nag, Nupur Descamps, Annabel Costers, Lars Dobson, Ruth Miller, Aleisha Rodrigues, Paulo Prčkovska, Vesna Comi, Giancarlo Kalincik, Tomas Mult Scler Relat Disord Correspondence BACKGROUND: Interferon-β, a disease-modifying therapy (DMT) for MS, may be associated with less severe COVID-19 in people with MS. RESULTS: Among 5,568 patients (83.4% confirmed COVID-19), interferon-treated patients had lower risk of severe COVID-19 compared to untreated, but not to glatiramer-acetate, dimethyl-fumarate, or pooled other DMTs. CONCLUSIONS: In comparison to other DMTs, we did not find evidence of protective effects of interferon-β on the severity of COVID-19, though compared to the untreated, the course of COVID19 was milder among those on interferon-β. This study does not support the use of interferon-β as a treatment to reduce COVID-19 severity in MS. Elsevier B.V. 2022-10 2022-07-25 /pmc/articles/PMC9310378/ /pubmed/35917745 http://dx.doi.org/10.1016/j.msard.2022.104072 Text en © 2022 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Correspondence Simpson-Yap, Steve Pirmani, Ashkan De Brouwer, Edward Peeters, Liesbet M. Geys, Lotte Parciak, Tina Helme, Anne Hillert, Jan Moreau, Yves Edan, Gilles Spelman, Tim Sharmin, Sifat McBurney, Robert Schmidt, Hollie Bergmann, Arnfin Braune, Stefan Stahmann, Alexander Middleton, Rodden Salter, Amber Bebo, Bruce van der Walt, Anneke Butzkueven, Helmut Ozakbas, Serkan Karabudak, Rana Boz, Cavit Alroughani, Raed Rojas, Juan I van der Mei, Ingrid Sciascia do Olival, Guilherme Magyari, Melinda Alonso, Ricardo Nicholas, Richard Chertcoff, Anibal Zabalza, Ana Arrambide, Georgina Nag, Nupur Descamps, Annabel Costers, Lars Dobson, Ruth Miller, Aleisha Rodrigues, Paulo Prčkovska, Vesna Comi, Giancarlo Kalincik, Tomas Severity of COVID19 infection among patients with multiple sclerosis treated with interferon-β |
| title | Severity of COVID19 infection among patients with multiple sclerosis treated with interferon-β |
| title_full | Severity of COVID19 infection among patients with multiple sclerosis treated with interferon-β |
| title_fullStr | Severity of COVID19 infection among patients with multiple sclerosis treated with interferon-β |
| title_full_unstemmed | Severity of COVID19 infection among patients with multiple sclerosis treated with interferon-β |
| title_short | Severity of COVID19 infection among patients with multiple sclerosis treated with interferon-β |
| title_sort | severity of covid19 infection among patients with multiple sclerosis treated with interferon-β |
| topic | Correspondence |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9310378/ https://www.ncbi.nlm.nih.gov/pubmed/35917745 http://dx.doi.org/10.1016/j.msard.2022.104072 |
| work_keys_str_mv | AT simpsonyapsteve severityofcovid19infectionamongpatientswithmultiplesclerosistreatedwithinterferonb AT pirmaniashkan severityofcovid19infectionamongpatientswithmultiplesclerosistreatedwithinterferonb AT debrouweredward severityofcovid19infectionamongpatientswithmultiplesclerosistreatedwithinterferonb AT peetersliesbetm severityofcovid19infectionamongpatientswithmultiplesclerosistreatedwithinterferonb AT geyslotte severityofcovid19infectionamongpatientswithmultiplesclerosistreatedwithinterferonb AT parciaktina severityofcovid19infectionamongpatientswithmultiplesclerosistreatedwithinterferonb AT helmeanne severityofcovid19infectionamongpatientswithmultiplesclerosistreatedwithinterferonb AT hillertjan severityofcovid19infectionamongpatientswithmultiplesclerosistreatedwithinterferonb AT moreauyves severityofcovid19infectionamongpatientswithmultiplesclerosistreatedwithinterferonb AT edangilles severityofcovid19infectionamongpatientswithmultiplesclerosistreatedwithinterferonb AT spelmantim severityofcovid19infectionamongpatientswithmultiplesclerosistreatedwithinterferonb AT sharminsifat severityofcovid19infectionamongpatientswithmultiplesclerosistreatedwithinterferonb AT mcburneyrobert severityofcovid19infectionamongpatientswithmultiplesclerosistreatedwithinterferonb AT schmidthollie severityofcovid19infectionamongpatientswithmultiplesclerosistreatedwithinterferonb AT bergmannarnfin severityofcovid19infectionamongpatientswithmultiplesclerosistreatedwithinterferonb AT braunestefan severityofcovid19infectionamongpatientswithmultiplesclerosistreatedwithinterferonb AT stahmannalexander severityofcovid19infectionamongpatientswithmultiplesclerosistreatedwithinterferonb AT middletonrodden severityofcovid19infectionamongpatientswithmultiplesclerosistreatedwithinterferonb AT salteramber severityofcovid19infectionamongpatientswithmultiplesclerosistreatedwithinterferonb AT bebobruce severityofcovid19infectionamongpatientswithmultiplesclerosistreatedwithinterferonb AT vanderwaltanneke severityofcovid19infectionamongpatientswithmultiplesclerosistreatedwithinterferonb AT butzkuevenhelmut severityofcovid19infectionamongpatientswithmultiplesclerosistreatedwithinterferonb AT ozakbasserkan severityofcovid19infectionamongpatientswithmultiplesclerosistreatedwithinterferonb AT karabudakrana severityofcovid19infectionamongpatientswithmultiplesclerosistreatedwithinterferonb AT bozcavit severityofcovid19infectionamongpatientswithmultiplesclerosistreatedwithinterferonb AT alroughaniraed severityofcovid19infectionamongpatientswithmultiplesclerosistreatedwithinterferonb AT rojasjuani severityofcovid19infectionamongpatientswithmultiplesclerosistreatedwithinterferonb AT vandermeiingrid severityofcovid19infectionamongpatientswithmultiplesclerosistreatedwithinterferonb AT sciasciadoolivalguilherme severityofcovid19infectionamongpatientswithmultiplesclerosistreatedwithinterferonb AT magyarimelinda severityofcovid19infectionamongpatientswithmultiplesclerosistreatedwithinterferonb AT alonsoricardo severityofcovid19infectionamongpatientswithmultiplesclerosistreatedwithinterferonb AT nicholasrichard severityofcovid19infectionamongpatientswithmultiplesclerosistreatedwithinterferonb AT chertcoffanibal severityofcovid19infectionamongpatientswithmultiplesclerosistreatedwithinterferonb AT zabalzaana severityofcovid19infectionamongpatientswithmultiplesclerosistreatedwithinterferonb AT arrambidegeorgina severityofcovid19infectionamongpatientswithmultiplesclerosistreatedwithinterferonb AT nagnupur severityofcovid19infectionamongpatientswithmultiplesclerosistreatedwithinterferonb AT descampsannabel severityofcovid19infectionamongpatientswithmultiplesclerosistreatedwithinterferonb AT costerslars severityofcovid19infectionamongpatientswithmultiplesclerosistreatedwithinterferonb AT dobsonruth severityofcovid19infectionamongpatientswithmultiplesclerosistreatedwithinterferonb AT milleraleisha severityofcovid19infectionamongpatientswithmultiplesclerosistreatedwithinterferonb AT rodriguespaulo severityofcovid19infectionamongpatientswithmultiplesclerosistreatedwithinterferonb AT prckovskavesna severityofcovid19infectionamongpatientswithmultiplesclerosistreatedwithinterferonb AT comigiancarlo severityofcovid19infectionamongpatientswithmultiplesclerosistreatedwithinterferonb AT kalinciktomas severityofcovid19infectionamongpatientswithmultiplesclerosistreatedwithinterferonb |